Singapore markets open in 8 hours 4 minutes

Recursion Pharmaceuticals, Inc. (RXRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.46+0.18 (+2.17%)
As of 12:56PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close8.28
Open8.39
Bid8.44 x 2100
Ask8.51 x 300
Day's range8.34 - 8.86
52-week range4.97 - 16.75
Volume2,400,507
Avg. volume5,306,798
Market cap2.011B
Beta (5Y monthly)0.85
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Recursion to Participate in Upcoming Investor Conferences

    SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Jefferies Healthcare Conference - June 5-6, 2024 45th Annual Goldman Sachs Healthcare Conference - June 10-13, 2024 Morgan Stanley 3rd Annual Life Sciences AI Summit - June 26-27, 2024 About Recursion Recursion is a clinical stage TechBio company leading the s

  • GlobeNewswire

    Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool

    Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in CRISPR-Cas9 gene knockouts and a debiasing (correcting) algorithm.SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics scientific findings that highli

  • GlobeNewswire

    Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board

    Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneurSALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert Hershberg, M.D., Ph.D, has been appointed the new Chair of the Board of Recursion, effective at the end of this term, as Martin Chavez exits after more than four years of leadership. “I’m ex